ArticleAJNR. American journal of neuroradiology2019
Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
Article in AJNR. American journal of neuroradiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.NeuroImage. Clinical · 2022Pooled it
- CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic review.NeuroImage. Clinical · 2020Pooled it
- Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.Journal of neurology · 2026Article
- ODC1 restricts meningeal B cell age-associated-like phenotype and function in multiple sclerosis: A human and experimental study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Beyond the leptomeningeal angioma: a comprehensive review of MR imaging features of Sturge-Weber Syndrome, from early vascular responses to tissue necrosis.Pediatric radiology · 2025Review
- Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms.Expert review of neurotherapeutics · 2025Review
- Alternative Venous Pathways: A Potential Key Imaging Feature for Early Diagnosis of Sturge-Weber Syndrome Type 1.AJNR. American journal of neuroradiology · 2025Article
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging.Neuroimaging clinics of North America · 2024Review
- The neuropathobiology of multiple sclerosis.Nature reviews. Neuroscience · 2024Review
- Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases.Cellular and molecular life sciences : CMLS · 2024Review
- The use of 7T MRI in multiple sclerosis: review and consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Brain communications · 2024Review
- Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?Therapeutic advances in neurological disorders · 2024Review
- Understanding the Pathophysiology and Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.Korean journal of radiology · 2023Review
- Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.Journal of neurology · 2023Article
- The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis.Frontiers in cellular neuroscience · 2023Review
- Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis.Frontiers in immunology · 2023Article
- Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.Frontiers in molecular neuroscience · 2023Review
- Time course of lesion-induced atrophy in multiple sclerosis.Journal of neurology · 2022Article
- Distinct roles of the meningeal layers in CNS autoimmunity.Nature neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background and purposeLeptomeningeal inflammation is associated with the development of global cortical gray matter atrophy in multiple sclerosis. However, its association with localized loss of tissue remains unclear. The purpose of this study was to evaluate the relationship between leptomeningeal contrast enhancement, a putative marker of leptomeningeal inflammation, and focal cortical thinning in MS. MATERIALS AND
methodsForty-three patients with relapsing-remitting MS and 15 with secondary-progressive MS were imaged on a 3T scanner. Cortical reconstruction was performed with FreeSurfer. Leptomeningeal contrast-enhancement foci were visually identified on 3D-FLAIR postcontrast images and confirmed using subtraction imaging. Leptomeningeal contrast-enhancement foci were mapped onto the cortex, and ROIs were obtained by dilating along the surface multiple times (
resultsDifferences between ipsilateral and contralateral ROIs progressively decreased with larger ROIs, but no significant effects were detected when considering the entire MS sample. In patients with relapsing-remitting MS only, significantly reduced cortical thickness was found for 5 dilations (-8.53%, corrected
conclusionsFocal leptomeningeal contrast enhancement is associated with reduced thickness of the surrounding cortex in patients with relapsing-remitting MS, but not in those with secondary-progressive MS. Our results suggest that pathology associated with the presence of leptomeningeal contrast-enhancement foci has a stronger, localized effect on cortical tissue loss earlier in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.